{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T05:03:32Z","timestamp":1649135012720},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1992,8,1]],"date-time":"1992-08-01T00:00:00Z","timestamp":712627200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutisch Weekblad Scientific Edition"],"published-print":{"date-parts":[[1992,8]]},"DOI":"10.1007\/bf01962542","type":"journal-article","created":{"date-parts":[[2005,8,2]],"date-time":"2005-08-02T05:08:56Z","timestamp":1122959336000},"page":"206-220","source":"Crossref","is-referenced-by-count":2,"title":["Dealing with sadness, madness and hostility"],"prefix":"10.1007","volume":"14","author":[{"given":"Anton J. M.","family":"Loonen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF01962542_CR1","first-page":"383","volume-title":"Goodman and Gilman's The pharmacological basis of therapeutics","author":"RJ Baldessarini","year":"1990","unstructured":"Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's The pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990:383\u2013435.","edition":"8th ed"},{"key":"BF01962542_CR2","first-page":"2257","volume-title":"Comprehensive textbook of Pychiatry\/III","author":"JM Davis","year":"1980","unstructured":"Davis JM. Antipsychotic drugs. In: Kaplan HI, Freedman AM, Sadock BJ, eds. Comprehensive textbook of Pychiatry\/III. 3rd ed. Baltimore: Williams & Wilkins, 1980:2257\u201389.","edition":"3rd ed"},{"key":"BF01962542_CR3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1600-0773.1973.tb01539.x","volume":"33","author":"L Terenius","year":"1973","unstructured":"Terenius L. Characteristics of the \u2018receptor\u2019 for narcotic analgesics in synaptic plasma membrane fraction from rat brain. Acta Pharmacol Toxicol 1973;33: 377\u201384.","journal-title":"Acta Pharmacol Toxicol"},{"key":"BF01962542_CR4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1126\/science.179.4077.1011","volume":"179","author":"CB Pert","year":"1973","unstructured":"Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science 1973;179:1011\u20134.","journal-title":"Science"},{"key":"BF01962542_CR5","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1073\/pnas.70.8.2243","volume":"70","author":"CB Pert","year":"1973","unstructured":"Pert CB, Snyder SH. Properties of opiate-receptor binding in rat brain. Proc Natl Acad Sci USA 1973;70: 2243\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF01962542_CR6","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1073\/pnas.70.7.1947","volume":"70","author":"EJ Simon","year":"1973","unstructured":"Simon EJ, Hiller JM, Edelman I. Stereospecific binding of the potent narcotic analgesic (3H)etorphine to rat-brain homogenate. Proc Natl Acad Sci USA 1973; 70:1947\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl","key":"BF01962542_CR7","first-page":"1","volume":"12","author":"S Watson","year":"1991","unstructured":"Watson S, Abbott A. TiPS receptor nomenclature supplement 1991. TiPS 1991;12 Suppl:1\u201336.","journal-title":"TiPS"},{"issue":"Suppl 3","key":"BF01962542_CR8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-2007-1014544","volume":"23","author":"SZ Langer","year":"1990","unstructured":"Langer SZ, Arbilla S, Tan S, Lloyd KG, George P, Allen J, Wick AE. Selectivity for omega-receptor subtypes as a strategy for the development of anxiolytic drugs. Pharmacopsychiatry 1990;23 Suppl 3:103\u20137.","journal-title":"Pharmacopsychiatry"},{"key":"BF01962542_CR9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0091-3057(88)90202-X","volume":"29","author":"SZ Langer","year":"1988","unstructured":"Langer SZ, Arbilla S. Imidazopyridines as a tool for the characterization of benzodiazepine receptors: a proposal for a pharmacological classification as omega receptor subtypes. Pharmacol Biochem Behav 1988;29: 763\u20136.","journal-title":"Pharmacol Biochem Behav"},{"key":"BF01962542_CR10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/347146a0","volume":"347","author":"P Sokoloff","year":"1990","unstructured":"Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990;347:146\u201351.","journal-title":"Nature"},{"key":"BF01962542_CR11","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/350610a0","volume":"350","author":"HH Tol Van","year":"1991","unstructured":"Van Tol HH, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350:610\u20134.","journal-title":"Nature"},{"key":"BF01962542_CR12","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/350614a0","volume":"350","author":"RK Sunahara","year":"1991","unstructured":"Sunahara RK, Guan HC, O'Dowd BF, et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 1991;350:614\u20139.","journal-title":"Nature"},{"key":"BF01962542_CR13","first-page":"4","volume":"12","author":"MR Tota","year":"1991","unstructured":"Tota MR, Candelore MR, Dixon RAF, Strader CD. Biophysical and genetic analysis of the ligand-binding site of the\u03b2-adrenoceptor. TiPS 1991;12:4\u20136.","journal-title":"TiPS"},{"key":"BF01962542_CR14","first-page":"335","volume":"3","author":"P Hartig","year":"1990","unstructured":"Hartig P, Kao HT, Macchi M, et al. The molecular biology of serotonin receptors. An overview. Neuropsychopharmacology 1990;3:335\u201347.","journal-title":"Neuropsychopharmacology"},{"key":"BF01962542_CR15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1073\/pnas.88.2.429","volume":"88","author":"I Gantz","year":"1991","unstructured":"Gantz I, Schaffer M, DelValle J, et al. Molecular cloning of a gene encoding the histamine H2 receptor. Proc Natl Acad Sci USA 1991;88:429\u201333.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF01962542_CR16","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1096\/fasebj.4.5.2155149","volume":"4","author":"RW Olsen","year":"1990","unstructured":"Olsen RW, Tobin AJ. Molecular biology of GABA-A receptors. FASEB J 1990;4:1469\u201380.","journal-title":"FASEB J"},{"key":"BF01962542_CR17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0166-2236(89)90054-4","volume":"12","author":"TI Bonner","year":"1989","unstructured":"Bonner TI. The molecular basis of muscarinic receptor diversity. Trends Neurosci 1989;12:148\u201351.","journal-title":"Trends Neurosci"},{"key":"BF01962542_CR18","first-page":"34","volume":"12","author":"ES Deneris","year":"1991","unstructured":"Deneris ES, Connolly J, Rogers SW, Duvoisin R. Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors. TiPS 1991;12:34\u201340.","journal-title":"TiPS"},{"key":"BF01962542_CR19","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/BF00449811","volume":"238","author":"WE Haefely","year":"1989","unstructured":"Haefely WE. Pharmacology of the benzodiazepine receptor. Eur Arch Psychiatry Neurol Sci 1989;238: 294\u2013301.","journal-title":"Eur Arch Psychiatry Neurol Sci"},{"key":"BF01962542_CR20","first-page":"452","volume":"11","author":"W Haefely","year":"1990","unstructured":"Haefely W, Martin JR, Schoch P. Novel anxiolytics that act as partial agonists at benzodiazepine receptors. TiPS 1990;11:452\u20136.","journal-title":"TiPS"},{"key":"BF01962542_CR21","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/0024-3205(75)90272-6","volume":"16","author":"BM Cox","year":"1975","unstructured":"Cox BM, Opheim KE, Teschemacher H, Goldstein A. A peptide-like substance from pituitary that acts like morphine. 2. Purification and properties. Life Sci 1975;16:1777\u201382.","journal-title":"Life Sci"},{"key":"BF01962542_CR22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/258577a0","volume":"258","author":"J Hughes","year":"1975","unstructured":"Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975;258:577\u201380.","journal-title":"Nature"},{"key":"BF01962542_CR23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0006-8993(75)90391-1","volume":"88","author":"J Hughes","year":"1975","unstructured":"Hughes J. Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine. Brain Res 1975;88:295\u2013308.","journal-title":"Brain Res"},{"key":"BF01962542_CR24","first-page":"3042","volume":"73","author":"N Ling","year":"1976","unstructured":"Ling N, Burgus R, Guillemin R. Isolation, primary structure, and synthesis of alpha-endorphin and gamma-endorphin, two peptides of hypothalamichypophysial origin with morphinomimetic activity. Proc Natl Acad Sci, USA 1976;73:3042\u20136.","journal-title":"Proc Natl Acad Sci, USA"},{"key":"BF01962542_CR25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1748-1716.1975.tb05863.x","volume":"94","author":"L Terenius","year":"1975","unstructured":"Terenius L, Wahlstrom A. Search for an endogenous ligand for the opiate receptor. Acta Physiol Scand 1975;94:74\u201381.","journal-title":"Acta Physiol Scand"},{"key":"BF01962542_CR26","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/0024-3205(75)90271-4","volume":"16","author":"H Teschemacher","year":"1975","unstructured":"Teschemacher H, Opheim KE, Cox BM, Goldstein A. A peptide-like substance from pituitary that acts like morphine. I. Isolation. Life Sci 1975:16;1771\u20135.","journal-title":"Life Sci"},{"key":"BF01962542_CR27","first-page":"1","volume":"18","author":"G Zetler","year":"1978","unstructured":"Zetler G. Active peptides in the nervous tissue: historical prospects. Adv Biochem Psychopharmacol 1978;18:1\u201321.","journal-title":"Adv Biochem Psychopharmacol"},{"key":"BF01962542_CR28","first-page":"831","volume":"75","author":"AJM Loonen","year":"1979","unstructured":"Loonen AJM, Soudijn W. Peptides with a dual function: central neuroregulators and gut hormones. J Physiol 1979;75:831\u201350.","journal-title":"J Physiol"},{"key":"BF01962542_CR29","first-page":"59","volume":"3","author":"AJM Loonen","year":"1982","unstructured":"Loonen AJM. Neurocommunication and psychotropic drugs. Pharm Int 1982;3:59\u201364.","journal-title":"Pharm Int"},{"key":"BF01962542_CR30","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0006-291X(05)80270-0","volume":"176","author":"N Rouissi","year":"1991","unstructured":"Rouissi N, Gitter BD, Waters DC, Howbert JJ, Nixon JA, Regoli D. Selectivity and specificity of new, nonpeptide, quinuclidine antagonists of substance P. Biochem Biophys Res Commun 1991;176:894\u2013901.","journal-title":"Biochem Biophys Res Commun"},{"key":"BF01962542_CR31","first-page":"232","volume":"12","author":"JN Crawley","year":"1991","unstructured":"Crawley JN. Cholecystokinin-dopamine interactions. TiPS 1991;12:232\u20136.","journal-title":"TiPS"},{"key":"BF01962542_CR32","first-page":"228","volume":"3","author":"J Cavagnaro","year":"1988","unstructured":"Cavagnaro J, Waterhouse GA, Lewis RM. Neuroendocrine-immune interactions: immunoregulatory signals mediated by neurohumoral agents. Year Immunol 1988;3:228\u201346.","journal-title":"Year Immunol"},{"key":"BF01962542_CR33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1037\/h0079226","volume":"61","author":"LT Vollhardt","year":"1991","unstructured":"Vollhardt LT. Psychoneuroimmunology: a literature review. Am J Orthopsychiatry 1991;61:35\u201347.","journal-title":"Am J Orthopsychiatry"},{"key":"BF01962542_CR34","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1037\/0033-2909.108.3.363","volume":"108","author":"A O'Leary","year":"1990","unstructured":"O'Leary A. Stress, emotion, and human immune function. Psychol Bull 1990;108:363\u201382.","journal-title":"Psychol Bull"},{"key":"BF01962542_CR35","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/0166-2236(89)90051-9","volume":"12","author":"JB Martin","year":"1989","unstructured":"Martin JB. Molecular genetic studies in the neuropsychiatric disorders. Trends Neurosci 1989;12:130\u20137.","journal-title":"Trends Neurosci"},{"issue":"Suppl 354","key":"BF01962542_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1989.tb03043.x","volume":"80","author":"RFW Diekstra","year":"1989","unstructured":"Diekstra RFW. Suicide and the attempted suicide: an international perspective. Acta Psychiatr Scand 1989;80 Suppl 354:1\u201324.","journal-title":"Acta Psychiatr Scand"},{"key":"BF01962542_CR37","first-page":"1129","volume-title":"Psychopharmacology. The third generation of progress","author":"CA Tamminga","year":"1987","unstructured":"Tamminga CA, Gerlach J. New neuroleptics and experimental antipsychotics in schizophrenia. In: Meltzer HY, ed. Psychopharmacology. The third generation of progress. New York: Raven Press, 1987:1129\u201340."},{"key":"BF01962542_CR38","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2165\/00003495-199040060-00008","volume":"40","author":"AN Wadworth","year":"1990","unstructured":"Wadworth AN, Heel RC. Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutical potential in schizophrenia. Drugs 1990;40:863\u201379.","journal-title":"Drugs"},{"key":"BF01962542_CR39","first-page":"123","volume":"7","author":"H Hall","year":"1989","unstructured":"Hall H, \u00d6gren SO, Kohler C, Magnusson O. Animal pharmacology of raclopride, a selective dopamine D2 antagonist. Psychopharmacol Ser 1989;7:123\u201330.","journal-title":"Psychopharmacol Ser"},{"key":"BF01962542_CR40","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0920-9964(91)90030-U","volume":"4","author":"AY Deutch","year":"1991","unstructured":"Deutch AY, Moghaddam B, Innis RB, et al. Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophren Res 1991;4:121\u201356.","journal-title":"Schizophren Res"},{"key":"BF01962542_CR41","first-page":"329","volume":"50","author":"JA Lieberman","year":"1989","unstructured":"Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989;50:329\u201338.","journal-title":"J Clin Psychiatry"},{"key":"BF01962542_CR42","doi-asserted-by":"crossref","first-page":"722","DOI":"10.2165\/00003495-199040050-00007","volume":"40","author":"A Fitton","year":"1990","unstructured":"Fitton A, Heel RC. Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 1990;40:722\u201347.","journal-title":"Drugs"},{"key":"BF01962542_CR43","first-page":"185","volume":"11","author":"RE Chipkin","year":"1990","unstructured":"Chipkin RE. D1 antagonist in clinical trial. TiPS 1990;11:185.","journal-title":"TiPS"},{"key":"BF01962542_CR44","first-page":"406","volume":"11","author":"J Hietala","year":"1990","unstructured":"Hietala J, Lappalainen J, Koulu M, Syvalahti E. Dopamine D1 receptor antagonism in schizophrenia: is there reduced risk of extrapyramidal side-effects? TiPS 1990;11:406\u201310.","journal-title":"TiPS"},{"key":"BF01962542_CR45","unstructured":"Anonymous. Pharmaprojects. New drugs in development. AN 016427 9101. Richmond: PJB Publications, 1991."},{"key":"BF01962542_CR46","first-page":"13","volume":"36","author":"G VandenBussche","year":"1990","unstructured":"VandenBussche G, Gelders YG, Heylen SL. El desarrollo de nuevas drogas antipsicoticas. Acta Psiquiatr Psicol Am Lat 1990;36:13\u201325.","journal-title":"Acta Psiquiatr Psicol Am Lat"},{"key":"BF01962542_CR47","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ddr.430080124","volume":"8","author":"A Reyntjens","year":"1986","unstructured":"Reyntjens A, Gelders YG, Hoppenbrouwers MLJA, VandenBussche G. Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin-S2 receptor blocker. Drug Devel Res 1986;8:205\u201311.","journal-title":"Drug Devel Res"},{"key":"BF01962542_CR48","first-page":"661","volume":"247","author":"JE Leysen","year":"1988","unstructured":"Leysen JE, Gommeren W, Eens A, DeChaffoy-DeCourcelles D, Stoof JC, Jansen PA. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661\u201370.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF01962542_CR49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1254\/jjp.53.321","volume":"53","author":"A Hirose","year":"1990","unstructured":"Hirose A, Kato T, Ohno Y et al. Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions. Jpn J Pharmacol 1990;53:321\u20139.","journal-title":"Jpn J Pharmacol"},{"issue":"Suppl 358","key":"BF01962542_CR50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0447.1990.tb05281.x","volume":"82","author":"SO \u00d6gren","year":"1990","unstructured":"\u00d6gren SO, Florvall L, Hall H, Magnusson O, Angeby-Moller K. Neuropharmacological and behavioural properties of remoxipride in the rat. Acta Psychiatr Scand 1990;82 Suppl 358:21\u20136.","journal-title":"Acta Psychiatr Scand"},{"key":"BF01962542_CR51","first-page":"49","volume":"11","author":"A Abbott","year":"1990","unstructured":"Abbott A. 5-HT3 antagonists and ligands for dopamine D1- and autoreceptors offer new leads for antipsychotic drugs. TiPS 1990;11:49\u201351.","journal-title":"TiPS"},{"key":"BF01962542_CR52","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2165\/00003495-198224030-00001","volume":"24","author":"RC Heel","year":"1982","unstructured":"Heel RC, Morley PA, Brogden RN, Carmine AA, Speight TM, Avery GS. Zimelidine. A review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 1982;24:169\u2013206.","journal-title":"Drugs"},{"key":"BF01962542_CR53","unstructured":"Anonymous. CSM update. Adverse reactions to antidepressants. BMJ 1985;291:1638."},{"key":"BF01962542_CR54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/jnnp.48.1.65","volume":"48","author":"J Fagius","year":"1985","unstructured":"Fagius J, Osterman PO, Sid\u00e9n A, Wiholm B-E. Guillain-Barr\u00e9 syndrome following zimeldine treatment. J Neurol Neurosurg Psychiatry 1985;48:65\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BF01962542_CR55","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00003495-198632040-00002","volume":"32","author":"P Benfield","year":"1986","unstructured":"Benfield P, Ward A. Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986;32:313\u201334.","journal-title":"Drugs"},{"key":"BF01962542_CR56","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00003495-198632060-00002","volume":"32","author":"P Benfield","year":"1986","unstructured":"Benfield P, Heel RC, Lewis SP. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986;32:481\u2013508.","journal-title":"Drugs"},{"key":"BF01962542_CR57","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2165\/00003495-199141030-00008","volume":"41","author":"RJ Milne","year":"1991","unstructured":"Milne RJ, Goa KL. Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and potential in depressive illness. Drugs 1991;41:450\u201377.","journal-title":"Drugs"},{"issue":"Suppl","key":"BF01962542_CR58","first-page":"46","volume":"49","author":"DP Doogan","year":"1988","unstructured":"Doogan DP, Caillard V. Sertraline: a new antidepressant. J Clin Psychiatry 1988;49 Suppl:46\u201351.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl B","key":"BF01962542_CR59","first-page":"13","volume":"51","author":"BK Koe","year":"1990","unstructured":"Koe BK. Preclinical pharmacology of sertraline: a potent and specific inhibitor of serotonin reuptake. J Clin Psychiatry 1990;51 Suppl B:13\u20137.","journal-title":"J Clin Psychiatry"},{"key":"BF01962542_CR60","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003495-199141020-00007","volume":"41","author":"KL Dechant","year":"1991","unstructured":"Dechant KL, Clissold SP. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991;41:225\u201353.","journal-title":"Drugs"},{"key":"BF01962542_CR61","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0028-3908(88)90149-9","volume":"27","author":"TH Boer De","year":"1988","unstructured":"De Boer TH, Maura G, Raiteri M, De Vos CJ, Wieringa J, Pinder RM. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology 1988;27:399\u2013408.","journal-title":"Neuropharmacology"},{"key":"BF01962542_CR62","first-page":"191","volume":"26","author":"WT Smith","year":"1990","unstructured":"Smith WT, Glaudin V, Panagides J, Gilvary E. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990;26:191\u20136.","journal-title":"Psychopharmacol Bull"},{"key":"BF01962542_CR63","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00007611-199102000-00017","volume":"84","author":"WA James","year":"1991","unstructured":"James WA, Lippmann S. Bupropion: overview and prescribing guidelines in depression. South Med J 1991;84:222\u20134.","journal-title":"South Med J"},{"key":"BF01962542_CR64","first-page":"1041","volume-title":"Psychopharmacology. The third generation of progress","author":"B Blackwell","year":"1987","unstructured":"Blackwell B. Newer antidepressant drugs. In: Meltzer HY, ed. Psychopharmacology. The third generation of progress. New York: Raven Press, 1987:1041\u20139."},{"key":"BF01962542_CR65","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000118596","volume":"22","author":"JP Macher","year":"1989","unstructured":"Macher JP, Sichel JP, Serre C, Von Frenckell R, Huck JC, Demarez JP. Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology 1989;22:77\u201382.","journal-title":"Neuropsychobiology"},{"key":"BF01962542_CR66","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-199001000-00005","volume":"5","author":"R Frenckell Von","year":"1990","unstructured":"Von Frenckell R, Ansseau M, Serre C, Sutet P. Pooling two controlled comparisons of milnacipran (F2207) and amitriptyline in endogenous inpatients. A new approach in dose ranging studies. Int Clin Psychopharmacol 1990;5:49\u201356.","journal-title":"Int Clin Psychopharmacol"},{"key":"BF01962542_CR67","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF00444686","volume":"98","author":"M Ansseau","year":"1989","unstructured":"Ansseau M, Von Frenckell R, Mertens C, et al. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Psychopharmacology 1989;98:163\u20138.","journal-title":"Psychopharmacology"},{"key":"BF01962542_CR68","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3109\/00498258909042306","volume":"19","author":"W Krause","year":"1989","unstructured":"Krause W, Kuhne G, Matthes H. Pharmacokinetics of the antidepressant rolipram in healthy volunteers. Xenobiotica 1989;19:683\u201392.","journal-title":"Xenobiotica"},{"key":"BF01962542_CR69","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1192\/bjp.154.3.287","volume":"154","author":"D Nutt","year":"1989","unstructured":"Nutt D, Glue P. Monoamine oxidase inhibitors: rehabilitation from recent research? Br J Psychiatry 1989;154:287\u201391.","journal-title":"Br J Psychiatry"},{"key":"BF01962542_CR70","unstructured":"Nolen WA, Bouvy PF, Haffmans J. MAO-inhibitors in resistant depression. Biol Psychiatry 1991;29:58S."},{"key":"BF01962542_CR71","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/archpsyc.1989.01810090029005","volume":"46","author":"FM Quitkin","year":"1989","unstructured":"Quitkin FM, McGrath PJ, Stewart JW, et al. Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression. Arch Gen Psychiatry 1989;46:787\u201393.","journal-title":"Arch Gen Psychiatry"},{"key":"BF01962542_CR72","first-page":"147","volume":"5","author":"A Delini-Stula","year":"1988","unstructured":"Delini-Stula A, Radeke E, Waldmeier PC. Basic and clinical aspects of the activity of the new monoamine oxidase inhibitors. Psychopharmacol Ser 1988;5: 147\u201358.","journal-title":"Psychopharmacol Ser"},{"issue":"Suppl 6","key":"BF01962542_CR73","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1192\/S0007125000297511","volume":"155","author":"R Amrein","year":"1989","unstructured":"Amrein R, Allen SR, Guentert TW, et al. The pharmacology of reversible monomamine oxidase inhibitors. Br J Psychiatry 1989;155 Suppl 6:66\u201371.","journal-title":"Br J Psychiatry"},{"issue":"Suppl 1","key":"BF01962542_CR74","first-page":"37","volume":"16","author":"G Laux","year":"1989","unstructured":"Laux G. Moclobemid in der Depressionsbehandlung \u2014 eine \u00dcbersicht. Psychiatr Prax 1989;16 Suppl 1:37\u201340.","journal-title":"Psychiatr Prax"},{"key":"BF01962542_CR75","first-page":"77","volume":"28","author":"M Stabl","year":"1989","unstructured":"Stabl M, Bizi\u00e8re K, Schmid-Burgk W, Amrein R. Review of comparative clinical trials. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states. J Neural Transm Suppl 1989;28:77\u201389.","journal-title":"J Neural Transm Suppl"},{"issue":"Suppl 1","key":"BF01962542_CR76","first-page":"32","volume":"16","author":"HJ M\u00f6ller","year":"1989","unstructured":"M\u00f6ller HJ, Wendt G. Brofaromin \u2014 ein selectiver, reversibler und kurzwirksamer MAO-A-Hemmer. Psychiatr Prax 1989;16 Suppl 1:32\u20136.","journal-title":"Psychiatr Prax"},{"key":"BF01962542_CR77","first-page":"100","volume":"13","author":"I Huybrechts","year":"1991","unstructured":"Huybrechts I. The pharmacology of alprazolam: a review. Clin Ther 1991;13:100\u201317.","journal-title":"Clin Ther"},{"key":"BF01962542_CR78","first-page":"186","volume":"22","author":"JP Feighner","year":"1986","unstructured":"Feighner JP. A review of controlled studies of adinazolam mesylate in patients with major depressive disorder. Psychopharmacol Bull 1986;22:186\u201391.","journal-title":"Psychopharmacol Bull"},{"key":"BF01962542_CR79","first-page":"148","volume":"49","author":"MD Warner","year":"1988","unstructured":"Warner MD, Peabody CA, Whiteford HA, Hollister LE. Alprazolam as an antidepressant. J Clin Psychiatry 1988;49:148\u201350.","journal-title":"J Clin Psychiatry"},{"key":"BF01962542_CR80","first-page":"93","volume-title":"Clinical Psychopharmacology","author":"DV Sheehan","year":"1984","unstructured":"Sheehan DV. The treatment of panic and phobic disorders. In: Bernstein JG, ed. Clinical Psychopharmacology. 2nd ed. Boston: John Wright, 1984;93\u2013109.","edition":"2nd ed"},{"key":"BF01962542_CR81","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/archpsyc.1988.01800290027004","volume":"45","author":"JC Ballenger","year":"1988","unstructured":"Ballenger JC, Burrows GD, DuPont RL Jr, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry 1988;45:413\u201322.","journal-title":"Arch Gen Psychiatry"},{"key":"BF01962542_CR82","first-page":"458","volume":"47","author":"DL Dunner","year":"1986","unstructured":"Dunner DL, Ishiki D, Avery DH, Wilson LG, Hyde TS. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry 1986:47;458\u201360.","journal-title":"J Clin Psychiatry"},{"key":"BF01962542_CR83","first-page":"69","volume":"52","author":"GE Tesar","year":"1991","unstructured":"Tesar GE, Rosenbaum JF, Pollack MH et al. Doubleblind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991;52:69\u201376.","journal-title":"J Clin Psychiatry"},{"key":"BF01962542_CR84","first-page":"418","volume":"50","author":"DS Charney","year":"1989","unstructured":"Charney DS, Woods SW. Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiatry 1989:50;418\u201323.","journal-title":"J Clin Psychiatry"},{"key":"BF01962542_CR85","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2165\/00003495-198632010-00003","volume":"32","author":"KL Goa","year":"1986","unstructured":"Goa KL, Heel RC. Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 1986;32:48\u201365.","journal-title":"Drugs"},{"key":"BF01962542_CR86","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/BF00187246","volume":"93","author":"J Gerlach","year":"1987","unstructured":"Gerlach J, Christensen JK, Christensen TL, Elley J, Jensen JP, Larsen SB. Suriclone and diazepam in the treatment of neurotic anxiety. A double-blind crossover trial. Psychopharmacology 1987;93:296\u2013300.","journal-title":"Psychopharmacology"},{"issue":"Suppl 3","key":"BF01962542_CR87","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1055\/s-2007-1014549","volume":"23","author":"PL Morselli","year":"1990","unstructured":"Morselli PL. On the therapeutic action of alpidem in anxiety disorders: an overview of the European data. Pharmacopsychiatry 1990;23 Suppl 3:129\u201334.","journal-title":"Pharmacopsychiatry"},{"key":"BF01962542_CR88","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0091-3057(88)90213-4","volume":"29","author":"D Wheatley","year":"1988","unstructured":"Wheatley D. New hypnotic agents: clinical studies in general practice. Pharmacol Biochem Behav 1988;29:811\u20133.","journal-title":"Pharmacol Biochem Behav"},{"key":"BF01962542_CR89","first-page":"1161","volume":"123","author":"PNJ Langendijk","year":"1988","unstructured":"Langendijk PNJ, Van Loenen AC, Jonker C. Farmacotherapie bij Alzheimer-type dementie [Pharmaco-therapy in Alzheimer-type dementia]. Pharm Weekbl 1988;123:1161\u201370.","journal-title":"Pharm Weekbl"},{"key":"BF01962542_CR90","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/bmj.300.6723.495","volume":"300","author":"G Chatellier","year":"1990","unstructured":"Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Francais d'Etude de la Tetrahydroaminoacridine. BMJ 1990;300:495\u20139.","journal-title":"BMJ"},{"key":"BF01962542_CR91","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199005033221804","volume":"322","author":"S Gauthier","year":"1990","unstructured":"Gauthier S, Bouchard R, Lamontagne A, et al. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study. N Engl J Med 1990;322:1272\u20136.","journal-title":"N Engl J Med"},{"key":"BF01962542_CR92","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1192\/bjp.157.6.894","volume":"157","author":"AL Nyth","year":"1990","unstructured":"Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry 1990;157:894\u2013901.","journal-title":"Br J Psychiatry"},{"issue":"Suppl","key":"BF01962542_CR93","first-page":"30","volume":"49","author":"DV Sheehan","year":"1988","unstructured":"Sheehan DV, Zak JP, Miller JA Jr, Fanous BS. Panic disorder: the potential role of serotonin reuptake inhibitors. J Clin Psychiatry 1988;49 Suppl:30\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 6","key":"BF01962542_CR94","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1192\/S0007125000297481","volume":"155","author":"MR Liebowitz","year":"1989","unstructured":"Liebowitz MR. Antidepressants in panic disorders. Br J Psychiatry 1989;155 Suppl 6:46\u201352.","journal-title":"Br J Psychiatry"},{"issue":"Suppl 360","key":"BF01962542_CR95","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-0447.1990.tb05321.x","volume":"82","author":"MR Liebowitz","year":"1990","unstructured":"Liebowitz MR, Hollander E, Schneier F, et al. Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatr Scand 1990;82 Suppl 360:29\u201334.","journal-title":"Acta Psychiatr Scand"},{"issue":"Suppl 3","key":"BF01962542_CR96","doi-asserted-by":"crossref","first-page":"91S","DOI":"10.1097\/00004714-199006001-00016","volume":"10","author":"DL Murphy","year":"1990","unstructured":"Murphy DL, Pato MT, Pigott TA. Obsessivecompulsive disorder: treatment with serotonin-selective uptake inhibitors, azapirones, and other agents. J Clin Psychopharmacol 1990;10 Suppl 3:91S\u2013100S.","journal-title":"J Clin Psychopharmacol"},{"key":"BF01962542_CR97","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2165\/00003495-199039010-00010","volume":"39","author":"D McTavish","year":"1990","unstructured":"McTavish D, Benfield P. Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 1990;39:136\u201353.","journal-title":"Drugs"},{"key":"BF01962542_CR98","first-page":"339","volume":"47","author":"HG Pope Jr","year":"1986","unstructured":"Pope HG Jr, Hudson JI. Antidepressant drug therapy for bulimia: current status. J Clin Psychiatry 1986: 47:339\u201345.","journal-title":"J Clin Psychiatry"},{"key":"BF01962542_CR99","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0361-9230(83)90196-X","volume":"11","author":"RE Frost","year":"1983","unstructured":"Frost RE, Messiha FS. Clinical uses of lithium salts. Brain Res Bull 1983;11:219\u201331.","journal-title":"Brain Res Bull"},{"key":"BF01962542_CR100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/00223980.1990.10543205","volume":"124","author":"JB Murray","year":"1990","unstructured":"Murray JB. New applications of lithium therapy. J Psychol 1990;124:55\u201373.","journal-title":"J Psychol"},{"issue":"Suppl","key":"BF01962542_CR101","first-page":"4","volume":"51","author":"JW Jefferson","year":"1990","unstructured":"Jefferson JW. Lithium: the present and the future. J Clin Psychiatry 1990;51 Suppl:4\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl","key":"BF01962542_CR102","first-page":"21","volume":"49","author":"JC Ballenger","year":"1988","unstructured":"Ballenger JC. The use of anticonvulsants in manicdepressive illness. J Clin Psychiatry 1988;49 Suppl:21\u20135.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl","key":"BF01962542_CR103","first-page":"9","volume":"51","author":"RM Post","year":"1990","unstructured":"Post RM. Non-lithium treatment for bipolar disorder. J Clin Psychiatry 1990;51 Suppl:9\u201319.","journal-title":"J Clin Psychiatry"},{"key":"BF01962542_CR104","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00005053-198605000-00005","volume":"174","author":"RM Greendyke","year":"1986","unstructured":"Greendyke RM, Kanter DR, Schuster DB, Verstreate S, Wootton J. Propranolol treatment of assaultive patients with organic brain disease. A double-blind crossover, placebo-controlled study. J Nerv Ment Dis 1986;174:290\u20134.","journal-title":"J Nerv Ment Dis"},{"key":"BF01962542_CR105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000118236","volume":"15","author":"J Ananth","year":"1986","unstructured":"Ananth J, Lin KM. Propranolol in psychiatry. Therapeutic uses and side effects. Neuropsychobiology 1986;15:20\u20137.","journal-title":"Neuropsychobiology"},{"key":"BF01962542_CR106","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/schbul\/13.4.705","volume":"13","author":"JL Berlant","year":"1987","unstructured":"Berlant JL. One more look at propranolol for the treatment of refractory schizophrenia. Schizophr Bull 1987;13:705\u201314.","journal-title":"Schizophr Bull"},{"key":"BF01962542_CR107","first-page":"372","volume":"25","author":"DJ Luchins","year":"1989","unstructured":"Luchins DJ, Dojka D. Lithium and propranolol in aggression and self-injurious behavior in the mentally retarded. Psychopharmacol Bull 1989;25:372\u20135.","journal-title":"Psychopharmacol Bull"},{"key":"BF01962542_CR108","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00004714-199002000-00003","volume":"10","author":"WW Fleischhacker","year":"1990","unstructured":"Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 1990;10:12\u201321.","journal-title":"J Clin Psychopharmacol"},{"key":"BF01962542_CR109","first-page":"81","volume":"6","author":"WS Bond","year":"1986","unstructured":"Bond WS. Psychiatric indications for clonidine: the neuropharmacologic and clinical basis. J Clin Psychopharmacol 1986;6:81\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"BF01962542_CR110","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0376-8716(88)90078-6","volume":"21","author":"M Gossop","year":"1988","unstructured":"Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend 1988;21:253\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"BF01962542_CR111","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0306-4530(86)90060-0","volume":"11","author":"M Dose","year":"1986","unstructured":"Dose M, Emrich HM, Cording-Tommel C, Von Zerssen D. Use of calcium antagonists in mania. Psychoneuroendocrinology 1986;11:241\u20133.","journal-title":"Psychoneuroendocrinology"},{"key":"BF01962542_CR112","first-page":"225","volume":"9","author":"WA Price","year":"1987","unstructured":"Price WA. Antipsychotic effects of verapamil in schizophrenia. Hillside J Clin Psychiatry 1987;9:225\u201330.","journal-title":"Hillside J Clin Psychiatry"},{"key":"BF01962542_CR113","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00004714-199010060-00006","volume":"10","author":"E Duncan","year":"1990","unstructured":"Duncan E, Adler L, Angrist B, Rotrosen J. Nifedipine in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1990;10:414\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"BF01962542_CR114","first-page":"1330","volume":"41","author":"WH Roccaforte","year":"1990","unstructured":"Roccaforte WH, Burke WJ. Use of psychostimulants for the elderly. Hosp Commun Psychiatry 1990;41:1330\u20133.","journal-title":"Hosp Commun Psychiatry"},{"key":"BF01962542_CR115","first-page":"241","volume":"50","author":"SL Satel","year":"1989","unstructured":"Satel SL, Nelson JC. Stimulants in the treatment of depression: a critical overview. J Clin Psychiatry 1989;50:241\u20139.","journal-title":"J Clin Psychiatry"},{"key":"BF01962542_CR116","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/mds.870010206","volume":"1","author":"A Walters","year":"1986","unstructured":"Walters A, Hening W, Chokroverty S, Fahn S. Opioid responsiveness in patients with neuroleptic-induced akathisia. Mov Disord 1986;1:119\u201327.","journal-title":"Mov Disord"},{"key":"BF01962542_CR117","first-page":"39","volume":"12","author":"AJM Loonen","year":"1992","unstructured":"Loonen AJM, Verwey HA, Roels PR, Van Bavel LP, Doorschot CH. Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A negative, double-blind, placebocontrolled trial. J Clin Psychopharmacol 1992;12:39\u201342.","journal-title":"J Clin Psychopharmacol"},{"key":"BF01962542_CR118","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archpsyc.1990.01810180077011","volume":"47","author":"WK Goodman","year":"1990","unstructured":"Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990;47:577\u201385.","journal-title":"Arch Gen Psychiatry"},{"key":"BF01962542_CR119","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00004850-198801000-00005","volume":"3","author":"JA Boer Den","year":"1988","unstructured":"Den Boer JA, Westenberg HG. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988;3: 59\u201374.","journal-title":"Int Clin Psychopharmacol"},{"key":"BF01962542_CR120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9343(86)90325-6","volume":"80","author":"AS Eison","year":"1986","unstructured":"Eison AS, Temple DL. Buspirone. Review of its pharmacology and current perspectives on its mechanism of action. Am J Med 1986;80:1\u20139.","journal-title":"Am J Med"},{"key":"BF01962542_CR121","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2165\/00003495-198632020-00002","volume":"32","author":"KL Goa","year":"1986","unstructured":"Goa KL, Ward A. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986;32:114\u201329.","journal-title":"Drugs"},{"issue":"Suppl 3","key":"BF01962542_CR122","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1097\/00004714-199006001-00002","volume":"10","author":"AS Eison","year":"1990","unstructured":"Eison AS. Azapirones: history of development. J Clin Psychopharmacol 1990:10 Suppl 3:2S\u20135S.","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl 3","key":"BF01962542_CR123","doi-asserted-by":"crossref","first-page":"26S","DOI":"10.1097\/00004714-199006001-00006","volume":"10","author":"MS Eison","year":"1990","unstructured":"Eison MS. Serotonin: a common neurobiologic substrate in anxiety and depression. J Clin Psychopharmacol 1990;10 Suppl 3:26S-30S.","journal-title":"J Clin Psychopharmacol"},{"key":"BF01962542_CR124","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1515\/DMDI.1990.8.1-2.85","volume":"8","author":"J Schipper","year":"1990","unstructured":"Schipper J, Tulp MT, Sijbesma H. Neurochemical profile of eltoprazine. Drug Metab Drug Interact 1990;8:85\u2013114.","journal-title":"Drug Metab Drug Interact"},{"key":"BF01962542_CR125","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/0166-2236(88)90011-2","volume":"11","author":"SJ Peroutka","year":"1988","unstructured":"Peroutka SJ. 5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization. Trends Neurosci 1988;11:496\u2013500.","journal-title":"Trends Neurosci"},{"key":"BF01962542_CR126","first-page":"135","volume":"340","author":"P Schoeffter","year":"1989","unstructured":"Schoeffter P, Hoyer D. How selective is GR 43175? Interactions with functional 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol 1989;340:135\u20138.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"BF01962542_CR127","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1385\/0-89603-122-5:299","volume-title":"Drugs as tools in neurotransmitter research","author":"JE Leysen","year":"1989","unstructured":"Leysen JE. Use of 5-HT receptor agonists and antagonists for the characterization of their respective receptor sites. In: Boulton AB, Baker GB, Juorio AV, eds. Drugs as tools in neurotransmitter research. Clifton:Humana Press, 1989:299\u2013348."},{"key":"BF01962542_CR128","first-page":"310","volume":"12","author":"AA Parsons","year":"1991","unstructured":"Parsons AA. 5-HT receptors in human and animal cerebrovasculature. TiPS 1991;12:310\u20135.","journal-title":"TiPS"},{"key":"BF01962542_CR129","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1523\/JNEUROSCI.09-10-03482.1989","volume":"9","author":"DJ McKenna","year":"1989","unstructured":"McKenna DJ, Peroutka SJ. Differentiation of 5-hydroxytryptamine2 receptor subtypes using (125I)-R-(\u2212)2,5-dimethoxy-4-iodo-phenylisopropylamine and (3H)-ketanserin. J Neurosci 1989;9:3482\u201390.","journal-title":"J Neurosci"},{"key":"BF01962542_CR130","first-page":"604","volume":"38","author":"T Branchek","year":"1990","unstructured":"Branchek T, Adham N, Macchi M, Kao HT, Hartig PR. (3H)-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and (3H)ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor. Mol Pharmacol 1990;38:604\u20139.","journal-title":"Mol Pharmacol"},{"key":"BF01962542_CR131","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1055\/s-2007-1017385","volume":"18","author":"DL Ceulemans","year":"1985","unstructured":"Ceulemans DL, Hoppenbrouwers ML, Gelders YG, Reyntjens AJ. The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 1985;18:303\u20135.","journal-title":"Pharmacopsychiatry"},{"key":"BF01962542_CR132","first-page":"111","volume":"7","author":"GM Bressa","year":"1987","unstructured":"Bressa GM, Marini S, Gregori S. Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam. Int J Clin Pharmacol Res 1987;7:111\u20139.","journal-title":"Int J Clin Pharmacol Res"},{"key":"BF01962542_CR133","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0447.1991.tb05533.x","volume":"83","author":"G Bersani","year":"1991","unstructured":"Bersani G, Pozzi F, Marini S, Grispini A, Pasini A, Ciani N. 5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. Acta Psychiatr Scand 1991;83:244\u20138.","journal-title":"Acta Psychiatr Scand"},{"key":"BF01962542_CR134","unstructured":"Duinkerke SJ, Botter PA, Van Haaften AJ, Boom AJ, Van Laarhoven JHM, Busard HLSM. Ritanserin in the treatment of negative symptoms in schizophrenic patients. Biol Psychiatry 1991;29:654S."},{"key":"BF01962542_CR135","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/00002826-199012000-00003","volume":"13","author":"G Bersani","year":"1990","unstructured":"Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 1990;13:500\u20136.","journal-title":"Clin Neuropharmacol"},{"key":"BF01962542_CR136","unstructured":"Anonymous. Ondansetron: Facts and comparisons. Hosp Pharm 1991;26:252\u2013253."},{"key":"BF01962542_CR137","first-page":"260","volume":"12","author":"I Izquierdo","year":"1991","unstructured":"Izquierdo I, Medina JH. GABA-A receptor modulation of memory: the role of endogenous benzodiazepines. TiPS 1991;12:260\u20135.","journal-title":"TiPS"},{"key":"BF01962542_CR138","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1515\/DMDI.1990.8.1-2.31","volume":"8","author":"B Olivier","year":"1990","unstructured":"Olivier B, Mos J, Rasmussen D. Behavioural pharmacology of the serenic eltoprazine. Drug Metab Drug Interact 1990;8:31\u201383.","journal-title":"Drug Metab Drug Interact"},{"key":"BF01962542_CR139","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.1985.03360160049009","volume":"254","author":"MF Goldsmith","year":"1985","unstructured":"Goldsmith MF. Drug review, approval process changing. JAMA 1985;254:2221,2227.","journal-title":"JAMA"},{"key":"BF01962542_CR140","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/clpt.1984.224","volume":"36","author":"L Sheck","year":"1984","unstructured":"Sheck L, Cox C, Davis HT, Trimble AG, Wardell WM, Hansen R. Success rates in the United States drug development system. Clin Pharmacol Ther 1984;36:574\u201383.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Pharmaceutisch Weekblad Scientific Edition"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01962542.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01962542\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01962542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T17:43:44Z","timestamp":1557769424000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01962542"}},"subtitle":["New psychotropic drug remedies for the future"],"short-title":[],"issued":{"date-parts":[[1992,8]]},"references-count":140,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1992,8]]}},"alternative-id":["BF01962542"],"URL":"https:\/\/doi.org\/10.1007\/bf01962542","relation":{},"ISSN":["0167-6555","1573-739X"],"issn-type":[{"value":"0167-6555","type":"print"},{"value":"1573-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,8]]}}}